[{"address1": "National Innovation Centre", "address2": "Suite 212a 2 4 Cornwallis Street Eveleigh", "city": "Sydney", "state": "NSW", "zip": "2015", "country": "Australia", "phone": "61 2 9209 4037", "fax": "61 2 9209 4037", "website": "https://www.claritypharmaceuticals.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.", "fullTimeEmployees": 41, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alan John Taylor Ph.D.", "title": "Executive Chairman", "fiscalYear": 2023, "totalPay": 565017, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Colin David Biggin Ph.D.", "title": "MD, CEO & Executive Director", "fiscalYear": 2023, "totalPay": 453013, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David K. Green BEc., CA", "title": "Chief Financial Officer", "fiscalYear": 2023, "totalPay": 158566, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shaemus  Gleason", "title": "Executive Vice President of Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Harris BSc., M.B.A., Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "totalPay": 130315, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lisa  Sadetskaya", "title": "Director of Corporate Communications.", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mary  Bennett", "title": "Head of Human Resource", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Michelle  Parker", "title": "Chief Clinical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Othon  Gervasio", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Vickery", "title": "Company Secretary", "fiscalYear": 2023, "totalPay": 108754, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 4.27, "dayLow": 4.27, "dayHigh": 4.29, "regularMarketOpen": 4.27, "regularMarketDayLow": 4.27, "regularMarketDayHigh": 4.29, "beta": 1.563, "volume": 4200, "regularMarketVolume": 4200, "averageVolume": 8450, "averageVolume10days": 8450, "averageDailyVolume10Day": 8450, "bid": 3.97, "ask": 4.14, "bidSize": 40000, "askSize": 40000, "marketCap": 1305590400, "fiftyTwoWeekLow": 4.0, "fiftyTwoWeekHigh": 4.61, "priceToSalesTrailing12Months": 137.63074, "fiftyDayAverage": 4.3, "twoHundredDayAverage": 4.3, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 1047689920, "floatShares": 178448932, "sharesOutstanding": 315360000, "heldPercentInsiders": 0.2969, "heldPercentInstitutions": 0.06726, "impliedSharesOutstanding": 316368000, "bookValue": 0.202, "priceToBook": 20.495049, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -30562508, "trailingEps": -0.08, "enterpriseToRevenue": 110.444, "enterpriseToEbitda": -32.115, "52WeekChange": -0.07174885, "SandP52WeekChange": 0.2623955, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "CLRPF", "underlyingSymbol": "CLRPF", "shortName": "Clarity Pharmaceuticals Ltd.", "longName": "Clarity Pharmaceuticals Ltd", "firstTradeDateEpochUtc": 1723728600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e3adc917-5183-3806-b4b8-3bebee6c5494", "messageBoardId": "finmb_263530964", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.14, "recommendationKey": "none", "totalCash": 37982804, "totalCashPerShare": 0.145, "ebitda": -32623064, "quickRatio": 10.905, "currentRatio": 11.762, "totalRevenue": 9486183, "revenuePerShare": 0.036, "returnOnAssets": -0.27666, "returnOnEquity": -0.45330003, "freeCashflow": -28502352, "operatingCashflow": -37663704, "revenueGrowth": -0.055, "grossMargins": 1.0, "operatingMargins": -3.3585901, "financialCurrency": "AUD", "trailingPegRatio": null, "__fetch_time": "2024-08-19"}]